Lycia Therapeutics (LYCA) closed at $28.85 on October 26, 2026, down 3.8% from the previous close, on volume of 953,806 shares (30-day average 2,245,004).
Data as of October 26, 2026.
At a glance: stocks gapping down premarket
Seeking Alpha News (Tue, 27-Oct 7:26 AM ET)
Lycia Therapeutics Updates Governance Ahead of Public Offering
TipRanks (Mon, 26-Oct 5:18 PM ET)
Globe Newswire (Mon, 26-Oct 4:12 PM ET)
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
Lycia Therapeutics trades on the NASDAQ stock market under the symbol LYCA.
As of October 27, 2026, LYCA stock price declined to $27.51 with 53,726 million shares trading.
LYCA has a market cap of $1.43 billion. This is considered a Small Cap stock.
LYCA support price is $22.07 and resistance is $35.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYCA shares will trade within this expected range on the day.
